BIOCON Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > biocon

Technical Analysis

Technical Strength: 7 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 51.5. According to RSI analysis, biocon is marginally weak. 4.0 BIOCON RSI Chart
MACD (?) MACD: 2.94 and Signal Line: 2.56. According to MACD analysis, biocon is technically strong. 8.0 BIOCON MACD Chart
Simple Moving Average (?) According to simple moving average analysis, biocon is in a strong uptrend. Major support levels are 1117.325, 1109.451, 962.2825. 10.0 BIOCON Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, biocon is in a strong uptrend. Major support levels are 1115.283, 1097.408, 955.6542. 10.0 BIOCON Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.507. 5.0 BIOCON Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above 61.8% and 50% level. Support is at 1102.775 and 1082.6619. Resistance level is 1122.8881. 8.0 BIOCON Fibonacci Retracement Chart
Average True Range (?) ATR: 36.4 NA BIOCON Average True Range Chart
Average Directional Index (?) ADX is 15.8 which means BIOCON is in a trading range and there is no trend. NA BIOCON Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
April 27, 2017
Open Price 1127.0
High Price 1155.0
Low Price 1114.75
Close Price 1120.6
Absolute Change -6.4
Percentage Change -0.568%
Weekly Change 0.34%
Monthly Change -1.72%
Yearly Change 103%
52-week high 1188.0
52-week low 550.85
Corporate Actions
ExDate Purpose
June 22, 2016 ANNUAL GENERAL MEETING
March 17, 2016 INT DIV-RS 5 PER SHARE
March 17, 2016 INTERIM DIVIDEND
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.759
Confidence in Beta5.48%
Market Capital Rs. 22409.0 Cr
Diluted Trailing Twelve Months (TTM) Earnings Per Share (EPS) Rs. 43.67
TTM Price-to-Earnings (P/E) Ratio 25.7
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 27 April 2017: Deliverable Quantity:2.39e+05 NA BIOCON Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 27 April 2017: Daily Volatility:0.4986 NA BIOCON Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 27 April 2017: PCR_OI:0.523 PCR:0.396 NA BIOCON PCR Chart
Premium (?) 27 April 2017 Premium: 0.95 Futures OI:1552800.0 NA BIOCON Premium Chart
Option_MAX_OI (?) 27 April 2017: Price:1120.6 Put with maximum OI:1100.0 Call with maximum OI:1200.0 NA BIOCON Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
April 27, 2017 1121.55 1552800.0 4647.0 5376.0 1120.6
May 25, 2017 1126.15 3146400.0 4602.0 5625.0 1120.6
June 29, 2017 1126.35 25200.0 60.0 62.0 1120.6

Announcements

April 11, 2017 KiraDisc. under Reg.30 of SEBI (SAST) Reg.2011an Mazumdar Shaw has submitted to the Exchange vide letter dated a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
March 30, 2017 BiocAnalysts/Institutional Investor Meet/Con. Call Updatescon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates
See all Announcements

Board Meetings

Date Meeting Date Purpose
April 25, 2017 April 27, 2017 The Results/Dividend/Bonus Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on April 27, 2017 inter alia, to consider, approve and take on record, the audited financial results (both standalone and consolidated) of the Company for the year ended March 31, 2017 amongst other routine matters recommendation of final dividend , if any , for the financial year 2016-17. The Company has now informed the Exchange that the board to consider and recommend to issue bonus share.(purpose revised).
April 20, 2017 April 27, 2017 The Results/Dividend Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on April 27, 2017 inter alia, to consider, approve and take on record, the audited financial results (both standalone and consolidated) of the Company for the year ended March 31, 2017 amongst other routine matters. The Company has now informed the Exchange that the board also considered and recommendation of final dividend , if any , for the financial year 2016-17.(purpose revised).
See all Board Meetings

BIOCON is part of...

Index Weightage
NFTYMCAP50 NA

Intraday Pivot Points

S3 S2 S1 Pivot R1 R2 R3
Rs. 1065 Rs. 1090 Rs. 1105 Rs. 1130 Rs. 1145 Rs. 1170 Rs. 1186